In GBM patients treated at recurrence with axitinib, a selective inhibitor of VEGFR-1, 2 and 3, a significant increase of the percentage of Treg within CD4+ T cell was observed after 6 weeks of treatment in the case of progressive disease [14]. This evidence concerns the gene CD4 and glioblastoma.